Immune checkpoint blockade including anti-PD-1/PD-L1 and anti-CTLA-4, designed to amplify endogenous anti-tumor T cell responses, has showed much success in certain cancers, such as melanoma and non-small cell lung cancer [200, 201]. Here, PDCD1 is linked to non-small cell lung carcinoma.